Evidence map›Paper›PMID 40038834›Full record

ArticleCancer & metabolism2025

Obesity and overweight in R/R DLBCL patients is associated with a better response to treatment of R2-GDP-GOTEL trial. Potential role of NK CD8 + cells and vitamin D.

Lourdes Hontecillas-Prieto, Daniel J García-Domínguez, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Eduardo Ríos-Herranz, Josep Gumà-Padrò, Mariano Provencio-Pulla, Antonio Rueda-Domínguez and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lourdes Hontecillas-Prieto *Clinical Biochemistry Service, Virgen Macarena University Hospital, University of Seville, Seville, Spain.
Daniel J García-Domínguez *Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Seville, Spain.
Carlos Jiménez-CorteganaDepartment of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Seville, Spain.
Esteban Nogales-FernándezClinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain.
Natalia Palazón-CarriónClinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain.
Alejandro Martín García-SanchoDepartment of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, University of Salamanca, Salamanca, Spain.
Eduardo Ríos-HerranzDepartment of Hematology, Hospital Universitario de Valme, Seville, Spain.
Josep Gumà-PadròDepartment of Clinical Oncology, Hospital Universitari Sant Joan de Reus URV, IISPV, Reus, Spain.
Mariano Provencio-PullaDepartment of Medical Oncology, Facultad de Medicina, Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, IDIPHISA, Madrid, Spain.
Antonio Rueda-DomínguezDepartment of Hematology/Clinical Oncology, Hospital Costa del Sol, Marbella, Spain.
Luis de la Cruz-MerinoClinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain. luis.cruz.sspa@juntadeandalucia.es.
Víctor Sánchez-MargaletClinical Biochemistry Service, Virgen Macarena University Hospital, University of Seville, Seville, Spain. margalet@us.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma worldwide and is characterized by its heterogeneity. Although first-line therapy improves survival outcomes for DLBCL patients, approximately one third will relapse, often with a poor prognosis. Among the factors influencing prognosis and response to treatment in cancer patients, including those with lymphoma, overweight and obesity have emerged as significant considerations. However, the role of excess weight in DLBCL remains controversial, with studies reporting both negative and positive effects on cancer outcomes. In this translational substudy of the R2-GDP-GOTEL trial, we have evaluated the impact of excess weight as a predictor of treatment response and survival in patients with relapsed/refractory (R/R) DLBCL, and examining its relationship with immune cell dynamics.

methodsOf the 79 patients who received the R2-GDP scheme in the phase II trial, weight and height parameters were obtained in 75 patients before starting treatment. Blood samples were analyzed by flow cytometry. Statistical analyses were performed to determine the prognostic value of overweight and obesity at baseline in R/R DLBCL patients.

resultsOur results indicate that overweight (including obese) patients exhibit longer survival compared to patients of ideal weight. This group also demonstrated a reduction of regulatory T cells with supposedly protumor activity and an increase of Natural Killer (NK)-like T cells with supposedly antitumor activity. Additionally, we have found that excess weight correlates with better treatment response, associated with elevated levels of vitamin D and CD8 + NK cells.

conclusionsOur findings suggest that excess weight does not exacerbate the progression of DLBCL. Instead, it appears to confer a survival advantage and improve treatment response, with the immune system playing a possible pivotal role in mediating these effects.

trial registrationEudraCT, ID:2014-001620-29.

Indexed as

CD8 + Natural Killer cellsDiffuse Large B Cell LymphomaObesity paradoxR2-GDP-GOTELResponse to treatmentVitamin D

Identifiers

PMID40038834
PMCPMC11881355

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.